Loading…

Sunitinib in metastatic renal cell carcinoma patients with brain metastases

BACKGROUND: In a broad patient population with metastatic renal cell carcinoma (RCC), enrolled in an open‐label, expanded access program (EAP), the safety profile of sunitinib was manageable, and efficacy results were encouraging. Here, the authors report results for patients with baseline brain met...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2011-02, Vol.117 (3), p.501-509
Main Authors: Gore, Martin E., Hariharan, Subramanian, Porta, Camillo, Bracarda, Sergio, Hawkins, Robert, Bjarnason, Georg A., Oudard, Stéphane, Lee, Se‐Hoon, Carteni, Giacomo, Nieto, Alejandra, Yuan, Jinyu, Szczylik, Cezary
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4272-c4d60732c3a02da16e6ed337494732335c6ad4060cf3bc35c46536ece084f66f3
cites cdi_FETCH-LOGICAL-c4272-c4d60732c3a02da16e6ed337494732335c6ad4060cf3bc35c46536ece084f66f3
container_end_page 509
container_issue 3
container_start_page 501
container_title Cancer
container_volume 117
creator Gore, Martin E.
Hariharan, Subramanian
Porta, Camillo
Bracarda, Sergio
Hawkins, Robert
Bjarnason, Georg A.
Oudard, Stéphane
Lee, Se‐Hoon
Carteni, Giacomo
Nieto, Alejandra
Yuan, Jinyu
Szczylik, Cezary
description BACKGROUND: In a broad patient population with metastatic renal cell carcinoma (RCC), enrolled in an open‐label, expanded access program (EAP), the safety profile of sunitinib was manageable, and efficacy results were encouraging. Here, the authors report results for patients with baseline brain metastases participating in this global EAP. METHODS: Previously treated and treatment‐naive metastatic RCC patients ≥18 years received sunitinib 50 mg orally, once daily, on Schedule 4/2. Safety was assessed regularly, tumor measurements done per local practice, and survival data collected where possible. Analyses were done in the modified intention‐to‐treat (ITT) population, consisting of all patients who received ≥1 dose of sunitinib. RESULTS: As of December 2007, 4564 patients had enrolled in 52 countries. Of these enrollees, 4371 were included in the modified ITT population, of whom 321 (7%) had baseline brain metastases and had received a median of 3 treatment cycles (range 1‐25). Reasons for their discontinuation included lack of efficacy (32%) and adverse events (8%). The most common grade 3‐4 treatment‐related adverse events were fatigue and asthenia (both 7%), thrombocytopenia (6%), and neutropenia (5%), the incidence of which were comparable to that for the overall EAP population. Of 213 evaluable patients, 26 (12%) had an objective response. Median progression‐free survival and overall survival were 5.6 months (95% CI, 5.2‐6.1) and 9.2 months (95% CI, 7.8‐10.9), respectively. CONCLUSIONS: In patients with brain metastases from RCC, the safety profile of sunitinib was comparable to that in the general metastatic RCC population, and sunitinib showed evidence of antitumor activity. Cancer 2011. © 2010 American Cancer Society. Three hundred twenty‐one patients with brain metastases from RCC were enrolled in a global, open‐label, expanded access program of sunitinib. The safety profile of sunitinib was comparable to that in the general metastatic RCC population, and sunitinib showed evidence of antitumor activity.
doi_str_mv 10.1002/cncr.25452
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_846902519</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>846902519</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4272-c4d60732c3a02da16e6ed337494732335c6ad4060cf3bc35c46536ece084f66f3</originalsourceid><addsrcrecordid>eNp90FtLwzAUB_AgipuXFz-A9EUUofPk2vZRijccCl7At5KmKUbabCYtY9_ezE73tpeEk_xyTvgjdIJhggHIlbLKTQhnnOygMYYsiQEzsovGAJDGnNGPETrw_iuUCeF0H40IpIIkLB2jx9fems5YU0bGRq3upO9kZ1TktJVNpHQTFumUsbNWRvNwpW3no4XpPqPSyc0br_0R2qtl4_Xxej9E77c3b_l9PH2-e8ivp7FiJCFhrQQklCgqgVQSCy10RWnCMhZOKeVKyIqBAFXTUoWSCU6FVhpSVgtR00N0PvSdu9l3r31XtMavfiqtnvW-SJnIgHCcBXmxVWJCU0x4xkmglwNVbua903Uxd6aVbllgKFYxF6uYi9-YAz5d9-3LVlf_9C_XAM7WQHolm9pJq4zfOJpkkDERHB7cwjR6uWVkkT_lL8PwH-aSk-4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1238125952</pqid></control><display><type>article</type><title>Sunitinib in metastatic renal cell carcinoma patients with brain metastases</title><source>Wiley:Jisc Collections:Wiley Read and Publish Open Access 2024-2025 (reading list)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Gore, Martin E. ; Hariharan, Subramanian ; Porta, Camillo ; Bracarda, Sergio ; Hawkins, Robert ; Bjarnason, Georg A. ; Oudard, Stéphane ; Lee, Se‐Hoon ; Carteni, Giacomo ; Nieto, Alejandra ; Yuan, Jinyu ; Szczylik, Cezary</creator><creatorcontrib>Gore, Martin E. ; Hariharan, Subramanian ; Porta, Camillo ; Bracarda, Sergio ; Hawkins, Robert ; Bjarnason, Georg A. ; Oudard, Stéphane ; Lee, Se‐Hoon ; Carteni, Giacomo ; Nieto, Alejandra ; Yuan, Jinyu ; Szczylik, Cezary</creatorcontrib><description>BACKGROUND: In a broad patient population with metastatic renal cell carcinoma (RCC), enrolled in an open‐label, expanded access program (EAP), the safety profile of sunitinib was manageable, and efficacy results were encouraging. Here, the authors report results for patients with baseline brain metastases participating in this global EAP. METHODS: Previously treated and treatment‐naive metastatic RCC patients ≥18 years received sunitinib 50 mg orally, once daily, on Schedule 4/2. Safety was assessed regularly, tumor measurements done per local practice, and survival data collected where possible. Analyses were done in the modified intention‐to‐treat (ITT) population, consisting of all patients who received ≥1 dose of sunitinib. RESULTS: As of December 2007, 4564 patients had enrolled in 52 countries. Of these enrollees, 4371 were included in the modified ITT population, of whom 321 (7%) had baseline brain metastases and had received a median of 3 treatment cycles (range 1‐25). Reasons for their discontinuation included lack of efficacy (32%) and adverse events (8%). The most common grade 3‐4 treatment‐related adverse events were fatigue and asthenia (both 7%), thrombocytopenia (6%), and neutropenia (5%), the incidence of which were comparable to that for the overall EAP population. Of 213 evaluable patients, 26 (12%) had an objective response. Median progression‐free survival and overall survival were 5.6 months (95% CI, 5.2‐6.1) and 9.2 months (95% CI, 7.8‐10.9), respectively. CONCLUSIONS: In patients with brain metastases from RCC, the safety profile of sunitinib was comparable to that in the general metastatic RCC population, and sunitinib showed evidence of antitumor activity. Cancer 2011. © 2010 American Cancer Society. Three hundred twenty‐one patients with brain metastases from RCC were enrolled in a global, open‐label, expanded access program of sunitinib. The safety profile of sunitinib was comparable to that in the general metastatic RCC population, and sunitinib showed evidence of antitumor activity.</description><identifier>ISSN: 0008-543X</identifier><identifier>ISSN: 1097-0142</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.25452</identifier><identifier>PMID: 20862748</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents - therapeutic use ; Antitumor activity ; Asthenia ; Biological and medical sciences ; Brain ; Brain Neoplasms - drug therapy ; Brain Neoplasms - mortality ; Brain Neoplasms - secondary ; Carcinoma, Renal Cell - drug therapy ; Carcinoma, Renal Cell - mortality ; Carcinoma, Renal Cell - pathology ; Data processing ; Disease-Free Survival ; expanded access program ; Fatigue ; Female ; Humans ; Indoles - adverse effects ; Indoles - therapeutic use ; Kidney Neoplasms - drug therapy ; Kidney Neoplasms - mortality ; Kidney Neoplasms - pathology ; Male ; Medical sciences ; Metastases ; Middle Aged ; Neurology ; Neutropenia ; Pyrroles - adverse effects ; Pyrroles - therapeutic use ; renal cell carcinoma ; sunitinib ; Survival ; Thrombocytopenia ; Tumors ; Tumors of the nervous system. Phacomatoses</subject><ispartof>Cancer, 2011-02, Vol.117 (3), p.501-509</ispartof><rights>Copyright © 2010 American Cancer Society</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2010 American Cancer Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4272-c4d60732c3a02da16e6ed337494732335c6ad4060cf3bc35c46536ece084f66f3</citedby><cites>FETCH-LOGICAL-c4272-c4d60732c3a02da16e6ed337494732335c6ad4060cf3bc35c46536ece084f66f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=23790946$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20862748$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gore, Martin E.</creatorcontrib><creatorcontrib>Hariharan, Subramanian</creatorcontrib><creatorcontrib>Porta, Camillo</creatorcontrib><creatorcontrib>Bracarda, Sergio</creatorcontrib><creatorcontrib>Hawkins, Robert</creatorcontrib><creatorcontrib>Bjarnason, Georg A.</creatorcontrib><creatorcontrib>Oudard, Stéphane</creatorcontrib><creatorcontrib>Lee, Se‐Hoon</creatorcontrib><creatorcontrib>Carteni, Giacomo</creatorcontrib><creatorcontrib>Nieto, Alejandra</creatorcontrib><creatorcontrib>Yuan, Jinyu</creatorcontrib><creatorcontrib>Szczylik, Cezary</creatorcontrib><title>Sunitinib in metastatic renal cell carcinoma patients with brain metastases</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND: In a broad patient population with metastatic renal cell carcinoma (RCC), enrolled in an open‐label, expanded access program (EAP), the safety profile of sunitinib was manageable, and efficacy results were encouraging. Here, the authors report results for patients with baseline brain metastases participating in this global EAP. METHODS: Previously treated and treatment‐naive metastatic RCC patients ≥18 years received sunitinib 50 mg orally, once daily, on Schedule 4/2. Safety was assessed regularly, tumor measurements done per local practice, and survival data collected where possible. Analyses were done in the modified intention‐to‐treat (ITT) population, consisting of all patients who received ≥1 dose of sunitinib. RESULTS: As of December 2007, 4564 patients had enrolled in 52 countries. Of these enrollees, 4371 were included in the modified ITT population, of whom 321 (7%) had baseline brain metastases and had received a median of 3 treatment cycles (range 1‐25). Reasons for their discontinuation included lack of efficacy (32%) and adverse events (8%). The most common grade 3‐4 treatment‐related adverse events were fatigue and asthenia (both 7%), thrombocytopenia (6%), and neutropenia (5%), the incidence of which were comparable to that for the overall EAP population. Of 213 evaluable patients, 26 (12%) had an objective response. Median progression‐free survival and overall survival were 5.6 months (95% CI, 5.2‐6.1) and 9.2 months (95% CI, 7.8‐10.9), respectively. CONCLUSIONS: In patients with brain metastases from RCC, the safety profile of sunitinib was comparable to that in the general metastatic RCC population, and sunitinib showed evidence of antitumor activity. Cancer 2011. © 2010 American Cancer Society. Three hundred twenty‐one patients with brain metastases from RCC were enrolled in a global, open‐label, expanded access program of sunitinib. The safety profile of sunitinib was comparable to that in the general metastatic RCC population, and sunitinib showed evidence of antitumor activity.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antitumor activity</subject><subject>Asthenia</subject><subject>Biological and medical sciences</subject><subject>Brain</subject><subject>Brain Neoplasms - drug therapy</subject><subject>Brain Neoplasms - mortality</subject><subject>Brain Neoplasms - secondary</subject><subject>Carcinoma, Renal Cell - drug therapy</subject><subject>Carcinoma, Renal Cell - mortality</subject><subject>Carcinoma, Renal Cell - pathology</subject><subject>Data processing</subject><subject>Disease-Free Survival</subject><subject>expanded access program</subject><subject>Fatigue</subject><subject>Female</subject><subject>Humans</subject><subject>Indoles - adverse effects</subject><subject>Indoles - therapeutic use</subject><subject>Kidney Neoplasms - drug therapy</subject><subject>Kidney Neoplasms - mortality</subject><subject>Kidney Neoplasms - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Metastases</subject><subject>Middle Aged</subject><subject>Neurology</subject><subject>Neutropenia</subject><subject>Pyrroles - adverse effects</subject><subject>Pyrroles - therapeutic use</subject><subject>renal cell carcinoma</subject><subject>sunitinib</subject><subject>Survival</subject><subject>Thrombocytopenia</subject><subject>Tumors</subject><subject>Tumors of the nervous system. Phacomatoses</subject><issn>0008-543X</issn><issn>1097-0142</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNp90FtLwzAUB_AgipuXFz-A9EUUofPk2vZRijccCl7At5KmKUbabCYtY9_ezE73tpeEk_xyTvgjdIJhggHIlbLKTQhnnOygMYYsiQEzsovGAJDGnNGPETrw_iuUCeF0H40IpIIkLB2jx9fems5YU0bGRq3upO9kZ1TktJVNpHQTFumUsbNWRvNwpW3no4XpPqPSyc0br_0R2qtl4_Xxej9E77c3b_l9PH2-e8ivp7FiJCFhrQQklCgqgVQSCy10RWnCMhZOKeVKyIqBAFXTUoWSCU6FVhpSVgtR00N0PvSdu9l3r31XtMavfiqtnvW-SJnIgHCcBXmxVWJCU0x4xkmglwNVbua903Uxd6aVbllgKFYxF6uYi9-YAz5d9-3LVlf_9C_XAM7WQHolm9pJq4zfOJpkkDERHB7cwjR6uWVkkT_lL8PwH-aSk-4</recordid><startdate>20110201</startdate><enddate>20110201</enddate><creator>Gore, Martin E.</creator><creator>Hariharan, Subramanian</creator><creator>Porta, Camillo</creator><creator>Bracarda, Sergio</creator><creator>Hawkins, Robert</creator><creator>Bjarnason, Georg A.</creator><creator>Oudard, Stéphane</creator><creator>Lee, Se‐Hoon</creator><creator>Carteni, Giacomo</creator><creator>Nieto, Alejandra</creator><creator>Yuan, Jinyu</creator><creator>Szczylik, Cezary</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>20110201</creationdate><title>Sunitinib in metastatic renal cell carcinoma patients with brain metastases</title><author>Gore, Martin E. ; Hariharan, Subramanian ; Porta, Camillo ; Bracarda, Sergio ; Hawkins, Robert ; Bjarnason, Georg A. ; Oudard, Stéphane ; Lee, Se‐Hoon ; Carteni, Giacomo ; Nieto, Alejandra ; Yuan, Jinyu ; Szczylik, Cezary</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4272-c4d60732c3a02da16e6ed337494732335c6ad4060cf3bc35c46536ece084f66f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antitumor activity</topic><topic>Asthenia</topic><topic>Biological and medical sciences</topic><topic>Brain</topic><topic>Brain Neoplasms - drug therapy</topic><topic>Brain Neoplasms - mortality</topic><topic>Brain Neoplasms - secondary</topic><topic>Carcinoma, Renal Cell - drug therapy</topic><topic>Carcinoma, Renal Cell - mortality</topic><topic>Carcinoma, Renal Cell - pathology</topic><topic>Data processing</topic><topic>Disease-Free Survival</topic><topic>expanded access program</topic><topic>Fatigue</topic><topic>Female</topic><topic>Humans</topic><topic>Indoles - adverse effects</topic><topic>Indoles - therapeutic use</topic><topic>Kidney Neoplasms - drug therapy</topic><topic>Kidney Neoplasms - mortality</topic><topic>Kidney Neoplasms - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Metastases</topic><topic>Middle Aged</topic><topic>Neurology</topic><topic>Neutropenia</topic><topic>Pyrroles - adverse effects</topic><topic>Pyrroles - therapeutic use</topic><topic>renal cell carcinoma</topic><topic>sunitinib</topic><topic>Survival</topic><topic>Thrombocytopenia</topic><topic>Tumors</topic><topic>Tumors of the nervous system. Phacomatoses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gore, Martin E.</creatorcontrib><creatorcontrib>Hariharan, Subramanian</creatorcontrib><creatorcontrib>Porta, Camillo</creatorcontrib><creatorcontrib>Bracarda, Sergio</creatorcontrib><creatorcontrib>Hawkins, Robert</creatorcontrib><creatorcontrib>Bjarnason, Georg A.</creatorcontrib><creatorcontrib>Oudard, Stéphane</creatorcontrib><creatorcontrib>Lee, Se‐Hoon</creatorcontrib><creatorcontrib>Carteni, Giacomo</creatorcontrib><creatorcontrib>Nieto, Alejandra</creatorcontrib><creatorcontrib>Yuan, Jinyu</creatorcontrib><creatorcontrib>Szczylik, Cezary</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gore, Martin E.</au><au>Hariharan, Subramanian</au><au>Porta, Camillo</au><au>Bracarda, Sergio</au><au>Hawkins, Robert</au><au>Bjarnason, Georg A.</au><au>Oudard, Stéphane</au><au>Lee, Se‐Hoon</au><au>Carteni, Giacomo</au><au>Nieto, Alejandra</au><au>Yuan, Jinyu</au><au>Szczylik, Cezary</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sunitinib in metastatic renal cell carcinoma patients with brain metastases</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2011-02-01</date><risdate>2011</risdate><volume>117</volume><issue>3</issue><spage>501</spage><epage>509</epage><pages>501-509</pages><issn>0008-543X</issn><issn>1097-0142</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND: In a broad patient population with metastatic renal cell carcinoma (RCC), enrolled in an open‐label, expanded access program (EAP), the safety profile of sunitinib was manageable, and efficacy results were encouraging. Here, the authors report results for patients with baseline brain metastases participating in this global EAP. METHODS: Previously treated and treatment‐naive metastatic RCC patients ≥18 years received sunitinib 50 mg orally, once daily, on Schedule 4/2. Safety was assessed regularly, tumor measurements done per local practice, and survival data collected where possible. Analyses were done in the modified intention‐to‐treat (ITT) population, consisting of all patients who received ≥1 dose of sunitinib. RESULTS: As of December 2007, 4564 patients had enrolled in 52 countries. Of these enrollees, 4371 were included in the modified ITT population, of whom 321 (7%) had baseline brain metastases and had received a median of 3 treatment cycles (range 1‐25). Reasons for their discontinuation included lack of efficacy (32%) and adverse events (8%). The most common grade 3‐4 treatment‐related adverse events were fatigue and asthenia (both 7%), thrombocytopenia (6%), and neutropenia (5%), the incidence of which were comparable to that for the overall EAP population. Of 213 evaluable patients, 26 (12%) had an objective response. Median progression‐free survival and overall survival were 5.6 months (95% CI, 5.2‐6.1) and 9.2 months (95% CI, 7.8‐10.9), respectively. CONCLUSIONS: In patients with brain metastases from RCC, the safety profile of sunitinib was comparable to that in the general metastatic RCC population, and sunitinib showed evidence of antitumor activity. Cancer 2011. © 2010 American Cancer Society. Three hundred twenty‐one patients with brain metastases from RCC were enrolled in a global, open‐label, expanded access program of sunitinib. The safety profile of sunitinib was comparable to that in the general metastatic RCC population, and sunitinib showed evidence of antitumor activity.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>20862748</pmid><doi>10.1002/cncr.25452</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0008-543X
ispartof Cancer, 2011-02, Vol.117 (3), p.501-509
issn 0008-543X
1097-0142
1097-0142
language eng
recordid cdi_proquest_miscellaneous_846902519
source Wiley:Jisc Collections:Wiley Read and Publish Open Access 2024-2025 (reading list); EZB-FREE-00999 freely available EZB journals
subjects Adult
Aged
Aged, 80 and over
Antineoplastic Agents - therapeutic use
Antitumor activity
Asthenia
Biological and medical sciences
Brain
Brain Neoplasms - drug therapy
Brain Neoplasms - mortality
Brain Neoplasms - secondary
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - mortality
Carcinoma, Renal Cell - pathology
Data processing
Disease-Free Survival
expanded access program
Fatigue
Female
Humans
Indoles - adverse effects
Indoles - therapeutic use
Kidney Neoplasms - drug therapy
Kidney Neoplasms - mortality
Kidney Neoplasms - pathology
Male
Medical sciences
Metastases
Middle Aged
Neurology
Neutropenia
Pyrroles - adverse effects
Pyrroles - therapeutic use
renal cell carcinoma
sunitinib
Survival
Thrombocytopenia
Tumors
Tumors of the nervous system. Phacomatoses
title Sunitinib in metastatic renal cell carcinoma patients with brain metastases
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A31%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sunitinib%20in%20metastatic%20renal%20cell%20carcinoma%20patients%20with%20brain%20metastases&rft.jtitle=Cancer&rft.au=Gore,%20Martin%20E.&rft.date=2011-02-01&rft.volume=117&rft.issue=3&rft.spage=501&rft.epage=509&rft.pages=501-509&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/cncr.25452&rft_dat=%3Cproquest_cross%3E846902519%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4272-c4d60732c3a02da16e6ed337494732335c6ad4060cf3bc35c46536ece084f66f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1238125952&rft_id=info:pmid/20862748&rfr_iscdi=true